Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ImmunoGen Begins ADC Trial | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

ImmunoGen Begins ADC Trial

Targets EGFR in NSCLC, SCCHN and other solid tumors

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

ImmunoGen has begun a Phase I trial of its EGFR-targeting antibody-drug conjugate (ADC), IMGN289. IMGN289 will be evaluated in a multi-center trial designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and anticancer activity of the compound, administered weekly, in patients with non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck cancer (SCCHN), or other EGFR-positive solid tumors.

Once its maximum tolerated dose is defined in the dose-finding part of the trial, the activity of IMGN289 will be evaluated in disease-specific patient cohorts. The ones planned currently include SCCHN, squamous cell NSCLC, and NSCLC resistant to EGFR inhibitors.

IMGN289 is designed to bind to and kill cancer cells that highly express EGFR, also known as HER1. It contains an EGFR-targeting antibody developed by ImmunoGen with the company’s potent cell-killing agent, DM1, attached using its thioether linker. This design is also used in the approved HER2-targeting product, Kadcyla, marketed by Roche.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics